AstraZeneca PLC — Director's Dealing 2018

Sep 26, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Entasis Therapeutics Holdings Inc. (ETTX)
CIK: 0001724344
Period of Report: 2018-09-25

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: ASTRAZENECA AB (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (33499900)		Indirect

Footnotes

F1: All of these securities are owned by AstraZeneca AB, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca AB, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any. The principal business address of AstraZeneca AB is SE-151 85 Sodertalje, Sweden.

F2: Each share of Series A Preferred Stock is convertible at any time, at the option of the holder, into Common Stock, on a 20.728-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.